Abstract
Obesity is a well-established risk factor for the development of atrial fibrillation, and weight reduction has a beneficial effect on the natural course of the arrhythmia. In light of reports suggesting the positive impact of glucagon-like peptide-1 analogs on various metabolic parameters, especially weight reduction, they may potentially represent an effective therapeutic option for patients with atrial fibrillation. Preclinical studies indicate that GLP-1 analogs decrease susceptibility to atrial fibrillation by improving electrophysiological and structural parameters of the heart, however, clinical research outcomes provide conflicting results. The review article discusses the influence of obesity and weight reduction on the risk of atrial fibrillation development, as well as the role of GLP-1 analogs in the treatment of the arrhythmia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
